Early detection is a critical means of improving outcomes for cancer patients. When cancer is detected at stage I, patients have a 90 percent chance of survival. By contrast, if cancer is diagnosed at stage IV, patients have just a 5 percent or survival. The use of costly and invasive diagnostic approaches have been a barrier to early detection, but new technology has the potential to change that. Laboratory for Advanced Medicine is developing a simple blood-based test to detect cancer at its earliest stage. We spoke to Ken Chahine, CEO of Laboratory for Advanced Medicine, about the company’s blood-based test, how it works, and how it is prioritizing indications.

As the debate over drug pricing intensifies, biotech investor Peter Kolchinsky is weighing in with a proposed approach to balance access to medicines with the incentive for companies to invest in the development of innovative new therapies. In his new book The Great American Drug Deal, Kolchinsky makes the case for an approach to drug pricing that would ensure that the timely movement of innovative drugs to generic versions while also suggesting mechanisms for cutting the price of therapeutics after patents and exclusivity periods expire when competition fails to arise. We spoke to Kolchinsky about The Great American Drug Deal, his notion of a biotech social contract, and why it’s critical that the industry think differently than it has in the past about approaches to reform drug pricing.

There is growing scientific evidence suggesting that Alzheimer’s disease may be an autoimmune condition. Whether it is or not may be an unsettled issue, but targeting neuroinflammation associated with the disease is viewed by some as a potential therapeutic strategy. INmune Bio is developing an experimental, second-generation, selective TNF inhibitor that targets neuroinflammation. It believes this approach can slow or stop the progression of cognitive and psychiatric symptoms associated with the disease. We spoke to R.J. Tesi, CEO of INmune Bio, about whether Alzheimer’s disease is an autoimmune condition, the role of neuroinflammation in the progress of the disease, and how his company’s experimental therapy differs from existing TNF inhibitors today.

The Gloucester Marine Genomics Institute is seeking to harness biotechnology to discover new therapeutics by studying the DNA of marine life. At the same time, the institute hopes to breathe new life into a 400-year old fishing village that houses it and create new opportunities there. We spoke to Andrea Bodnar, science director at the Gloucester Marine Genomics Institute, about marine biotechnology, the ocean as a source for novel therapeutics, and the institute’s efforts to transform the economy along Cape Ann.

The latest reports on the coronavirus outbreak put the number of infections at nearly 75,000 and deaths at more than 2,100. Against the backdrop of the outbreak, we spoke to Evan Loh, chairman of the Antimicrobials Working Group and CEO of Paratek Pharmaceuticals, about the global changes that are fueling the threat of infectious disease outbreaks, the state of the antimicrobial arsenal, and what needs to be done to spur the development of new agents to combat the rise deadly bugs.

Orchestra BioMed may play at the intersection of drugs and devices, but’s its business strategy is clearly drawn from the biopharmaceutical industry. The company develops its pipeline and then leverages strategic alliances with global partners who can best commercialize its products and maximize their potential. We spoke to David Hochman, CEO of Orchestra BioMed, about the company’s therapeutic devices, the large market opportunities it is targeting, and how it seeks to rewrite the way medtech companies think about partnering.

Psychedelics have long been viewed as having potential to treat a range of mental health disorders including depression, addiction, PTSD, and ADHD. Government policies, though, have long impeded studies of their benefits. Mind Medicine is developing a pipeline of therapies based on psychedelics in the hopes of developing needed medicines for psychiatric conditions. Its lead experimental therapy is an ibogaine-derived molecule for the treatment of opioid addiction. We spoke to Steve Hurst, founder and CEO of MindMed, about the potential for psychedelic-based medicines, what’s known about them to date, and the challenges of working with these substances.

The difficulty in diagnosing Alzheimer’s disease and identifying it at its earliest stages when interventions offer the best opportunity for success, is one of the critical challenges in addressing the neurodegenerative condition. CorTechs Labs has developed quantitative analysis software that allows physicians to analyze brain images to diagnose and monitor patients with the diseases. We spoke to Chris Airriess, CEO of CorTechs, about the difficulty in diagnosing Alzheimer’s disease today, how its technology works, and its efforts to marry its software to genetic data as a way to identify and monitor people who may be at risk of developing the disease.

As people age, the ability of their eyes to focus on objects near to them weakens. The condition, known as presbyopia, affects more than 1.8 billion people worldwide. Though reading glasses provide a solution to the problem, Orasis Pharmaceuticals is developing a corrective eyedrop it says will provide an alternative. We spoke to Elad Kedar, CEO of Orasis, about aging eyes, its experimental eye drop intended to allow people to free themselves from a dependency on reading glasses, and how it works.

Ben Zeskind likens Immuneering’s platform technology to noise-cancelling headphones. Infact, the company’s use of the term “Disease Cancelling Technology” speaks directly to that. The approach, he says, allows the company to build a pipeline of drug candidate that address aspects of disease that have eluded tradition drug development approaches. We spoke Zeskind, CEO of Immuneering, about the company’s evolution from its roots in bioinformatics, its movement into drug development, and how its proprietary platform technology works.